Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX), a global leader in 3D-printed biomimetic and bioresorbable implants, has entered a multi-year exclusive agreement with Majeton to commercialise its dental, orthodontic, and maxillofacial products across China, Hong Kong, and Macau.
Valued at over 12 million Chinese yuan, the deal includes upfront and milestone payments, with additional revenue expected from ongoing product supply, reflecting strong confidence in the regional market potential.
Majeton, a Southeast Asian sales, marketing, and distribution specialist backed by Hong Kong-listed Essex Bio-Technology, brings extensive expertise and a proven track record, with its products currently available in more than 13,500 hospitals and a 2024 turnover of HK$1.67 billion.
The partnership aligns with Osteopore’s strategy of collaborating with established players to accelerate commercialisation, deliver high-quality regenerative solutions, and positively impact patient outcomes.
Osteopore's products, clinically recognised for superior results in vertical bone augmentation, enter a Chinese dental bone graft substitute and membrane market valued at US$212 million in 2023 and projected to grow at a 14% CAGR to US$530 million by 2030.
Osteopore CEO Dr. Lim Yujing said the collaboration represents a significant milestone in the company’s Asia-Pacific expansion.